The Bristol Meyers news of a $74B acquisition of Celgene puts in perspective how these BPs can easily make $5B "bolt-on" acquisitions when they see potential with a start-up biotech. Makes it seem like $500M is small potatoes in their world. Hope this is the start of a robust pharma M&A season that includes B-OM and B-IBD!